Literature DB >> 16492569

AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70.

Amir H Salehi1, Stephen J Morris, Wai-Chi Ho, Kathleen M Dickson, Genevieve Doucet, Snezana Milutinovic, Jon Durkin, John W Gillard, Philip A Barker.   

Abstract

We describe a group of small-molecule inhibitors of Jun kinase (JNK)-dependent apoptosis. AEG3482, the parental compound, was identified in a screening effort designed to detect compounds that reduce apoptosis of neonatal sympathetic neurons after NGF withdrawal. We show that AEG3482 blocks apoptosis induced by the p75 neurotrophin receptor (p75NTR) or its cytosolic interactor, NRAGE, and demonstrate that AEG3482 blocks proapoptotic JNK activity. We show that AEG3482 induces production of heat shock protein 70 (HSP70), an endogenous inhibitor of JNK, and establish that HSP70 accumulation is required for the AEG3482-induced JNK blockade. We show that AEG3482 binds HSP90 and induces HSF1-dependent HSP70 mRNA expression and find that AEG3482 facilitates HSP70 production while retaining HSP90 chaperone activity. These studies establish that AEG3482 inhibits JNK activation and apoptosis by a mechanism involving induced expression of HSP proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492569     DOI: 10.1016/j.chembiol.2005.11.012

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  20 in total

Review 1.  Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.

Authors:  Daniel W Neef; Alex M Jaeger; Dennis J Thiele
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

2.  Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Authors:  Takrima Sadikot; Megan Swink; Jeffery D Eskew; Douglas Brown; Huiping Zhao; Bhaskar R Kusuma; Roger A Rajewski; Brian S J Blagg; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

Review 3.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

4.  Deconvoluting Stress-Responsive Proteostasis Signaling Pathways for Pharmacologic Activation Using Targeted RNA Sequencing.

Authors:  Julia M D Grandjean; Lars Plate; Richard I Morimoto; Michael J Bollong; Evan T Powers; R Luke Wiseman
Journal:  ACS Chem Biol       Date:  2019-03-13       Impact factor: 5.100

5.  Mapping of NRAGE domains reveals clues to cell viability in BMP signaling.

Authors:  Jennifer A Rochira; Rebecca A Cowling; Joshua S Himmelfarb; Tamara L Adams; Joseph M Verdi
Journal:  Apoptosis       Date:  2010-01       Impact factor: 4.677

6.  Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells.

Authors:  Behrang Alani; Rasoul Salehi; Payam Sadeghi; Mohammad Zare; Fariba Khodagholi; Ehsan Arefian; Mazdak Ganjalikhani Hakemi; Hadi Digaleh
Journal:  J Mol Neurosci       Date:  2014-03       Impact factor: 3.444

Review 7.  Protein homeostasis as a therapeutic target for diseases of protein conformation.

Authors:  Barbara Calamini; Richard I Morimoto
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 8.  Complex roles of NRAGE on tumor.

Authors:  Ge Zhang; Huandi Zhou; Xiaoying Xue
Journal:  Tumour Biol       Date:  2016-05-21

Review 9.  Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.

Authors:  Rick T Dobrowsky
Journal:  Curr Diab Rep       Date:  2016-08       Impact factor: 4.810

Review 10.  To fold or not to fold: modulation and consequences of Hsp90 inhibition.

Authors:  Laura B Peterson; Brian S J Blagg
Journal:  Future Med Chem       Date:  2009-05       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.